Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment

M. Y. Follo, D. Russo, C. Finelli, S. Mongiorgi, C. Clissa, C. Fil, C. Colombi, M. Gobbi, L. Manzoli, M. Piazzi, A. M. Martelli, L. Cocco

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Phosphoinositide-phospholipase C (PI-PLC) beta1 can be considered a specific target for demethylating therapy in high-risk myelodysplastic syndrome (MDS) patients, as azacitidine treatment has been associated with a PI-PLCbeta1-specific promoter demethylation, and induction of PI-PLCbeta1 gene and protein expression. However, little is known about the molecular effect of azacitidine in low-risk MDS or the functional mechanisms linked with azacitidine effect on PI-PLCbeta1 promoter. In the present study, we further investigated the role of epigenetic regulation of PI-PLCbeta1, mainly focusing on the structure of the PI-PLCbeta1 promoter. We first examined the effect of azacitidine on PI-PLCbeta1 promoter methylation and gene expression in low-risk MDS. Moreover, we studied the expression of key molecules associated with the nuclear inositide signaling pathways, such as cyclin D3. By applying a chromatin immunoprecipitation method, we also studied the correlation between the demethylating effect of azacitidine and the degree of recruitment to PI-PLCbeta1 promoter of some transcription factors implicated in hematopoietic stem cell proliferation and differentiation, as well as of the methyl-CpG-binding domain proteins, which specifically interact with methylated DNA. Taken together, our results hint at a specific involvement of PI-PLCbeta1 in epigenetic mechanisms, and are particularly consistent with the hypothesis of a role for PI-PLCbeta1 in azacitidine-induced myeloid differentiation.

Original languageEnglish
Pages (from-to)943-950
Number of pages8
JournalLeukemia
Volume26
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Azacitidine
Myelodysplastic Syndromes
Epigenomics
Therapeutics
Phospholipase C beta
Cyclin D3
Phosphoinositide Phospholipase C
Gene Expression
Chromatin Immunoprecipitation
Hematopoietic Stem Cells
Methylation
Cell Differentiation
Carrier Proteins
Transcription Factors
Cell Proliferation
DNA
Proteins

Keywords

  • azacitidine
  • methylation
  • myelodysplastic syndromes
  • nuclear signaling
  • PI-PLCbeta1

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Follo, M. Y., Russo, D., Finelli, C., Mongiorgi, S., Clissa, C., Fil, C., ... Cocco, L. (2012). Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. Leukemia, 26(5), 943-950. https://doi.org/10.1038/leu.2011.300

Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. / Follo, M. Y.; Russo, D.; Finelli, C.; Mongiorgi, S.; Clissa, C.; Fil, C.; Colombi, C.; Gobbi, M.; Manzoli, L.; Piazzi, M.; Martelli, A. M.; Cocco, L.

In: Leukemia, Vol. 26, No. 5, 05.2012, p. 943-950.

Research output: Contribution to journalArticle

Follo, MY, Russo, D, Finelli, C, Mongiorgi, S, Clissa, C, Fil, C, Colombi, C, Gobbi, M, Manzoli, L, Piazzi, M, Martelli, AM & Cocco, L 2012, 'Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment', Leukemia, vol. 26, no. 5, pp. 943-950. https://doi.org/10.1038/leu.2011.300
Follo, M. Y. ; Russo, D. ; Finelli, C. ; Mongiorgi, S. ; Clissa, C. ; Fil, C. ; Colombi, C. ; Gobbi, M. ; Manzoli, L. ; Piazzi, M. ; Martelli, A. M. ; Cocco, L. / Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. In: Leukemia. 2012 ; Vol. 26, No. 5. pp. 943-950.
@article{b9e586600c6044abb1e1c212bf050c7c,
title = "Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment",
abstract = "Phosphoinositide-phospholipase C (PI-PLC) beta1 can be considered a specific target for demethylating therapy in high-risk myelodysplastic syndrome (MDS) patients, as azacitidine treatment has been associated with a PI-PLCbeta1-specific promoter demethylation, and induction of PI-PLCbeta1 gene and protein expression. However, little is known about the molecular effect of azacitidine in low-risk MDS or the functional mechanisms linked with azacitidine effect on PI-PLCbeta1 promoter. In the present study, we further investigated the role of epigenetic regulation of PI-PLCbeta1, mainly focusing on the structure of the PI-PLCbeta1 promoter. We first examined the effect of azacitidine on PI-PLCbeta1 promoter methylation and gene expression in low-risk MDS. Moreover, we studied the expression of key molecules associated with the nuclear inositide signaling pathways, such as cyclin D3. By applying a chromatin immunoprecipitation method, we also studied the correlation between the demethylating effect of azacitidine and the degree of recruitment to PI-PLCbeta1 promoter of some transcription factors implicated in hematopoietic stem cell proliferation and differentiation, as well as of the methyl-CpG-binding domain proteins, which specifically interact with methylated DNA. Taken together, our results hint at a specific involvement of PI-PLCbeta1 in epigenetic mechanisms, and are particularly consistent with the hypothesis of a role for PI-PLCbeta1 in azacitidine-induced myeloid differentiation.",
keywords = "azacitidine, methylation, myelodysplastic syndromes, nuclear signaling, PI-PLCbeta1",
author = "Follo, {M. Y.} and D. Russo and C. Finelli and S. Mongiorgi and C. Clissa and C. Fil and C. Colombi and M. Gobbi and L. Manzoli and M. Piazzi and Martelli, {A. M.} and L. Cocco",
year = "2012",
month = "5",
doi = "10.1038/leu.2011.300",
language = "English",
volume = "26",
pages = "943--950",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment

AU - Follo, M. Y.

AU - Russo, D.

AU - Finelli, C.

AU - Mongiorgi, S.

AU - Clissa, C.

AU - Fil, C.

AU - Colombi, C.

AU - Gobbi, M.

AU - Manzoli, L.

AU - Piazzi, M.

AU - Martelli, A. M.

AU - Cocco, L.

PY - 2012/5

Y1 - 2012/5

N2 - Phosphoinositide-phospholipase C (PI-PLC) beta1 can be considered a specific target for demethylating therapy in high-risk myelodysplastic syndrome (MDS) patients, as azacitidine treatment has been associated with a PI-PLCbeta1-specific promoter demethylation, and induction of PI-PLCbeta1 gene and protein expression. However, little is known about the molecular effect of azacitidine in low-risk MDS or the functional mechanisms linked with azacitidine effect on PI-PLCbeta1 promoter. In the present study, we further investigated the role of epigenetic regulation of PI-PLCbeta1, mainly focusing on the structure of the PI-PLCbeta1 promoter. We first examined the effect of azacitidine on PI-PLCbeta1 promoter methylation and gene expression in low-risk MDS. Moreover, we studied the expression of key molecules associated with the nuclear inositide signaling pathways, such as cyclin D3. By applying a chromatin immunoprecipitation method, we also studied the correlation between the demethylating effect of azacitidine and the degree of recruitment to PI-PLCbeta1 promoter of some transcription factors implicated in hematopoietic stem cell proliferation and differentiation, as well as of the methyl-CpG-binding domain proteins, which specifically interact with methylated DNA. Taken together, our results hint at a specific involvement of PI-PLCbeta1 in epigenetic mechanisms, and are particularly consistent with the hypothesis of a role for PI-PLCbeta1 in azacitidine-induced myeloid differentiation.

AB - Phosphoinositide-phospholipase C (PI-PLC) beta1 can be considered a specific target for demethylating therapy in high-risk myelodysplastic syndrome (MDS) patients, as azacitidine treatment has been associated with a PI-PLCbeta1-specific promoter demethylation, and induction of PI-PLCbeta1 gene and protein expression. However, little is known about the molecular effect of azacitidine in low-risk MDS or the functional mechanisms linked with azacitidine effect on PI-PLCbeta1 promoter. In the present study, we further investigated the role of epigenetic regulation of PI-PLCbeta1, mainly focusing on the structure of the PI-PLCbeta1 promoter. We first examined the effect of azacitidine on PI-PLCbeta1 promoter methylation and gene expression in low-risk MDS. Moreover, we studied the expression of key molecules associated with the nuclear inositide signaling pathways, such as cyclin D3. By applying a chromatin immunoprecipitation method, we also studied the correlation between the demethylating effect of azacitidine and the degree of recruitment to PI-PLCbeta1 promoter of some transcription factors implicated in hematopoietic stem cell proliferation and differentiation, as well as of the methyl-CpG-binding domain proteins, which specifically interact with methylated DNA. Taken together, our results hint at a specific involvement of PI-PLCbeta1 in epigenetic mechanisms, and are particularly consistent with the hypothesis of a role for PI-PLCbeta1 in azacitidine-induced myeloid differentiation.

KW - azacitidine

KW - methylation

KW - myelodysplastic syndromes

KW - nuclear signaling

KW - PI-PLCbeta1

UR - http://www.scopus.com/inward/record.url?scp=84860769429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860769429&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.300

DO - 10.1038/leu.2011.300

M3 - Article

VL - 26

SP - 943

EP - 950

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -